Clearmind Medicine (Nasdaq: CMND) expands PTSD drug IP with Hong Kong filing
Rhea-AI Filing Summary
Clearmind Medicine Inc., a clinical-stage biotech focused on non-hallucinogenic neuroplastogen-derived treatments, has filed a patent application with the Hong Kong Patent Office for psychedelic-based compounds targeting Post-Traumatic Stress Disorder (PTSD) and other mental health disorders. The application is part of an exclusive worldwide licensing agreement with Yissum Research Development Company of the Hebrew University of Jerusalem, under which Clearmind holds global rights to develop, manufacture, and commercialize novel compounds developed at Yissum.
The company states that Hong Kong patent protection supports access to the Asian market and complements existing patent coverage in the United States, Europe, and other regions. Clearmind reports an intellectual property portfolio of 19 patent families, including 32 granted patents, and views this filing as further expansion of its global IP position in large markets such as PTSD, which is cited as a multi‑billion‑dollar therapeutic opportunity.
Positive
- None.
Negative
- None.
Filing Explained
The press-release paragraph is incorporated into named registration statements, without creating an issued Hong Kong patent.
As a Form 6-K, this report furnishes the company’s
The filing also states that the press release’s first paragraph is incorporated by reference into specified Form F-3 and Form S-8 registration statements, making that paragraph part of those filings to the extent it is not later superseded.
The incorporation changes the disclosure record for those registration statements, but the filing does not report an issuance, commercialization, proceeds, or a change in existing common holders’ ownership.
The next material milestone is a patent-office decision: the release says no assurance exists that a patent will issue or that any issued patent will be advantageous to Clearmind.
Key Figures
Key Terms
neuroplastogen-derived medical
Post-Traumatic Stress Disorder medical
exclusive worldwide licensing agreement regulatory
patent application regulatory
CAGR financial
AI-generated analysis. How Rhea-AI works. Not financial advice.
FAQ
What did Clearmind Medicine (CMND) disclose in its July 2026 Form 6-K?
How does the Hong Kong patent filing support Clearmind Medicine (CMND) strategically?
What market size does Clearmind Medicine (CMND) cite for PTSD treatments?
What is the scope of Clearmind Medicine’s (CMND) IP portfolio?
What therapeutic areas is Clearmind Medicine (CMND) focusing on?
What rights does Clearmind Medicine (CMND) have under its Yissum agreement?
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 6-K
Report of Foreign Private Issuer
Pursuant to Rule 13a-16 or 15d-16
under the Securities Exchange Act of 1934
For the month of: July 2026
Commission file number: 001-41557
CLEARMIND MEDICINE INC.
(Translation of registrant’s name into English)
101 – 1220 West 6th Avenue
Vancouver, British Columbia
(Address of principal executive offices)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F ☒ Form 40-F ☐
CONTENTS
Attached hereto and incorporated herein is the Registrant’s press release issued on July 20, 2026, titled “Clearmind Medicine Expends Global IP portfolio with Hong Kong Patent Filing for Novel Psychedelic Compounds; Targets Multi-Billion-Dollar PTSD Therapeutics Market”.
The first paragraph of the press release attached to this Form 6-K as Exhibit 99.1 is incorporated by reference into the Registrant’s Registration Statements on Form F-3 (File Nos. 333-275991, 333-270859, 333-273293, 333-290404, 333-293521 and 333-295455) and Form S-8 (File No. 333-283695), filed with the Securities and Exchange Commission, to be a part thereof from the date on which this report is submitted, to the extent not superseded by documents or reports subsequently filed or furnished.
1
EXHIBIT INDEX
| Exhibit No. | ||
| 99.1 | Press release titled: “Clearmind Medicine Expends Global IP portfolio with Hong Kong Patent Filing for Novel Psychedelic Compounds; Targets Multi-Billion-Dollar PTSD Therapeutics Market” |
2
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| Clearmind Medicine, Inc. | ||
| (Registrant) | ||
| Date: July 20, 2026 | By: | /s/ Adi Zuloff-Shani |
| Name: | Adi Zuloff-Shani | |
| Title: | Chief Executive Officer | |
3
Exhibit 99.1
Clearmind Medicine Expends Global IP portfolio with Hong Kong Patent Filing for Novel Psychedelic Compounds; Targets Multi-Billion-Dollar PTSD Therapeutics Market
Vancouver, Canada, July 20, 2026 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (“Clearmind”) (Nasdaq: CMND), a clinical-stage biotechnology company pioneering nonhallucinogenic neuroplastogen-derived treatments for Alcohol Use Disorder (“AUD”), addiction, and weight management, today announced the filing of a patent application with the Hong Kong Patent Office for innovative psychedelic compounds targeting the treatment of Post-Traumatic Stress Disorder (“PTSD”) and other mental health disorders.
The Hong Kong patent application forms part of Clearmind’s exclusive worldwide licensing agreement with Yissum Research Development Company of the Hebrew University of Jerusalem (“Yissum”). Under the terms of the licensing agreement, Clearmind holds exclusive global rights to develop, manufacture, and commercialize novel compounds developed at Yissum. Clearmind is responsible for advancing the development program in accordance with regulatory requirements.
According to recent market reports, the global PTSD treatment market is valued at approximately USD 18.5 billion in 2025 and is projected to reach USD 30.2 billion by 2035, growing at a CAGR of 5.0%.
This filing further strengthens Clearmind’s position as an innovator with a rapidly expanding global IP portfolio. Clearmind believes the Asian market- represents a major commercial opportunity, and securing patent protection in Hong Kong provides a strategic gateway for regional market access. This filing enhances Clearmind’s established patent coverage in the United States, Europe, and other key jurisdictions and reinforcing the Company’s long-term value creation strategy.
About Clearmind Medicine Inc.
Clearmind is a clinical-stage neuroplastogens pharmaceutical biotech company focused on the discovery and development of non-hallucinogenic, second generation, neuroplastogen-derived therapeutics to solve widespread and underserved health problems, including alcohol use disorder. Its primary objective is to research and develop psychedelic-based compounds and attempt to commercialize them as regulated medicines, foods, or supplements.
The Company’s intellectual portfolio currently consists of nineteen patent families, including 32 granted patents. The Company intends to seek additional patents for its compounds whenever warranted and will remain opportunistic regarding the acquisition of additional intellectual property to build its portfolio.
Shares of Clearmind are listed for trading on Nasdaq under the symbol “CMND.”
For further information, visit: https://www.clearmindmedicine.com or contact:
Investor Relations
invest@clearmindmedicine.com
www.Clearmindmedicine.com
Forward-Looking Statements:
This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act and other securities laws. Words such as “expects,” “anticipates,” “intends,” “plans,” “believes,” “seeks,” “estimates” and similar expressions or variations of such words are intended to identify forward-looking statements. For example, the Company is using forward-looking statements when it discusses its rapidly expanding global IP portfolio, the expected growth of the global post-traumatic stress disorder (PTSD) treatment market, its belief that the Asian market represents a major commercial opportunity, and securing patent protection in Hong Kong provides a strategic gateway for regional market access and the Company’s long-term value creation strategy. The Company cannot assure that any patent will issue as a result of a pending patent application or, if issued, whether it will issue in a form that will be advantageous to the Company. Forward-looking statements are not historical facts, and are based upon management’s current expectations, beliefs and projections, many of which, by their nature, are inherently uncertain. Such expectations, beliefs and projections are expressed in good faith. However, there can be no assurance that management’s expectations, beliefs and projections will be achieved, and actual results may differ materially from what is expressed in or indicated by the forward-looking statements. Forward-looking statements are subject to risks and uncertainties that could cause actual performance or results to differ materially from those expressed in the forward-looking statements. For a more detailed description of the risks and uncertainties affecting the Company, reference is made to the Company’s reports filed from time to time with the Securities and Exchange Commission (“SEC”), including, but not limited to, the risks detailed in the Company’s annual report on Form 20-F for the fiscal year ended October 31, 2025 and subsequent filings with the SEC. Forward-looking statements speak only as of the date the statements are made. The Company assumes no obligation to update forward-looking statements to reflect actual results, subsequent events or circumstances, changes in assumptions or changes in other factors affecting forward-looking information except to the extent required by applicable securities laws. If the Company does update one or more forward-looking statements, no inference should be drawn that the Company will make additional updates with respect thereto or with respect to other forward-looking statements. References and links to websites have been provided as a convenience, and the information contained on such websites is not incorporated by reference into this press release. Clearmind is not responsible for the contents of third-party websites.